This is irrespective of the common BP control agents (TD, CCB, and ACE inhibitors) used by patients to treat hypertension, with over half being on tri-therapy, over two-thirds having low to moderate treatment adherence, and almost none with high adherence. This evidence concerns the gene ACE and hypertensive disorder.